MedTrace Logo

Lecanemab for Early Onset Familial Alzheimer's Disease

NCT06883019 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 114

Last updated 2025-03-19

No results posted yet for this study

Summary

The goal of this observational study is to learn about the efficacy of Lecanemab treatment for early-onset familial Alzheimer's disease (AD) in patients under 65 years of age with a family history of AD. Participants will receive Lecanemab at a dosage of 10 mg/kg every two weeks for a total of 18 months and will undergo cognitive assessments, PET and MRI scans, blood/fluid tests and whole genome sequencing. The study will explore the effects of genetic and hereditary factors on the efficacy of Lecanemab treatment in early-onset familial AD patients.

Conditions

  • Alzheimer Disease

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Gang Wang · RenJi Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-13
Primary Completion
2027-06-30
Completion
2027-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06883019 on ClinicalTrials.gov